Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Patent symbols : Nvsef save search
Global Advanced Drug Delivery Systems Market Report 2024: Review of Patents and Patent Applications Filed on Drug Delivery Release Mechanisms and Novel Applications
Published: 2024-02-15 (Crawled : 23:00) - prnewswire.com
TRUMF | $16.488 -1.51% -17.59% 1.7K
|
Health Technology
|
| O: 0.79%
H: 0.0%
C: -3.21%
SNYNF | News | $92.7 -2.18% 77
|
Health Technology
|
| O: 1.66%
H: 0.0%
C: -1.59%
NVSEF | News | $95.11 5.4% 6.88% 490
|
Health Technology
|
| O: 1.66%
H: 0.0%
C: -1.04%
TRUMY | $16.94 3.1% 0.79% 51K
|
Manufacturing
|
| O: 0.27%
H: 0.0%
C: -2.6%
NVS | News | $95.12 0.81% 5.43% 2.3M
|
Health Technology
|
| O: 0.37%
H: 0.57%
C: 0.19%
JNJ | News | $149.12 0.82% 0.3% 7.2M
|
Health Technology
|
| O: -0.83%
H: 0.0%
C: 0.0%
ABBV | News | $167.89 0.89% 0.51% 3.6M
|
Health Technology
|
| O: 0.01%
H: 0.0%
C: 0.0%
SNY | News | $47.15 1.84% 1.75% 2M
|
Health Technology
|
| O: -0.6%
H: 0.0%
C: 0.0%
drug patent report review global advanced market
Biosimilars Market Research Report 2023 - Global Forecast to 2028 - Patent Expiries of Blockbuster Biologics and Research into New Indications Presents Opportunities
Published: 2023-07-05 (Crawled : 00:00) - prnewswire.com
NVS | News | $95.12 0.81% 5.43% 2.3M
|
Health Technology
|
| O: -1.17%
H: 0.63%
C: 0.22%
LLY | News | $731.33 0.69% 0.36% 1.7M
|
Health Technology
|
| O: -0.55%
H: 0.97%
C: 0.02%
AMRX | $5.37 -0.92% -0.93% 1.8M
|
Health Technology
|
| O: -2.54%
H: 10.78%
C: 10.04%
AMPH | $40.17 0.4% 0.45% 350K
|
Health Technology
|
| O: -0.52%
H: 1.38%
C: -0.38%
AMGN | News | $271.91 1.11% 1.12% 1.4M
|
Health Technology
|
| O: -0.43%
H: 0.48%
C: -0.86%
patent report research global market
Global Type 2 Diabetes Treatment Market Outlook Report 2022-2023 & 2027: Patent Cliff, Oral Antidiabetics, and Growing Focus on Accessibility and Affordability of Medicine Bolsters Growth
Published: 2023-01-04 (Crawled : 23:00) - prnewswire.com
AZNCF | News | $138.73 1.86% -4.19% 3.6K
|
Health Technology
|
| O: -0.93%
H: 3.08%
C: 3.08%
NVO | News | $125.26 2.08% 0.98% 3.5M
|
Health Technology
|
| O: -0.89%
H: 1.18%
C: 0.52%
NVS | News | $95.12 0.81% 5.43% 2.3M
|
Health Technology
|
| O: -0.85%
H: 0.2%
C: -0.29%
JNJ | News | $149.12 0.82% 0.3% 7.2M
|
Health Technology
|
| O: -0.62%
H: 0.54%
C: -0.12%
SNY | News | $47.15 1.84% 1.75% 2M
|
Health Technology
|
| O: -3.07%
H: 0.0%
C: 0.0%
AZN | News | $70.13 2.31% 2.24% 4.3M
|
Health Technology
|
| O: -0.49%
H: 1.65%
C: 0.94%
treatment patent global report growing diabetes growth market
Novartis plans to petition the U.S. Supreme Court to uphold validity of the Gilenya® (fingolimod) dosing regimen patent
Published: 2022-09-21 (Crawled : 06:00) - globenewswire.com
NVSEF | News | $95.11 5.4% 6.88% 490
|
Health Technology
|
| O: 0.98%
H: 0.0%
C: -1.99%
NVS | News | $95.12 0.81% 5.43% 2.3M
|
Health Technology
|
| O: -0.73%
H: 0.04%
C: -1.85%
gilenya patent novartis
Novartis statement regarding competition authority investigation into assertion of a patent
Published: 2022-09-15 (Crawled : 06:00) - globenewswire.com
NVS | News | $95.12 0.81% 5.43% 2.3M
|
Health Technology
|
| O: -0.12%
H: 0.66%
C: -0.09%
patent novartis
Novartis plans to petition the U.S. Court of Appeals for the Federal Circuit for further review to uphold validity of the Gilenya® (fingolimod) dosing regimen patent
Published: 2022-06-21 (Crawled : 20:00) - globenewswire.com
NVS | News | $95.12 0.81% 5.43% 2.3M
|
Health Technology
|
| O: -1.57%
H: 0.0%
C: 0.0%
gilenya patent novartis review
Immutep Announces Second Japanese Patent Grant for LAG-3 Antagonist Antibody LAG525
Published: 2022-03-18 (Crawled : 12:30) - globenewswire.com
NVSEF | News | $95.11 5.4% 6.88% 490
|
Health Technology
|
| O: 1.11%
H: 0.0%
C: 0.0%
NVS | News | $95.12 0.81% 5.43% 2.3M
|
Health Technology
|
| O: 1.17%
H: 1.2%
C: 1.01%
IMMP | $2.32 3.11% 3.43% 170K
|
Health Technology
|
| O: 3.31%
H: 11.74%
C: 10.32%
lag525 patent antibody grant granted
Novartis announces U.S. Court of Appeals for the Federal Circuit (CAFC) upholds validity of Gilenya® (fingolimod) dosage regimen patent
Published: 2022-01-04 (Crawled : 07:00) - globenewswire.com
NVS | News | $95.12 0.81% 5.43% 2.3M
|
Health Technology
|
| O: 0.17%
H: 0.12%
C: -0.62%
gilenya novartis als patent
Gainers vs Losers
| 73% | 27% |
Top 10 Gainers
MTTR | News M | $4.8 175.86% 63.6% 71M
|
AGBA | $2.5 100.0% 56.6% 200M
|
Finance
MLEC | $2.47 76.43% 42.62% 78M
|
n/a
NUWE | $0.334 29.96% 40.99% 2.5M
|
Manufacturing
EDBL | News | $6.26 66.49% 40.13% 16M
|
ATGL | $2.86 46.25% 32.8% 180K
|
ONFO | $0.6088 38.68% 27.74% 7.3M
|
n/a
VIVK | $1.43 33.65% 27.7% 530K
|
Professional, Scientific, and T...
MNTS | $0.5 35.69% 26.3% 4.7M
|
SDIG A | $3.64 35.32% 26.0% 990K
|
Your saved searches
Save your searches and get alerts when important news are released.